A Harris Win Could Boost FTC, NIH Drug Pricing Roles Given Presumptive Candidate’s Prior Anticompetitive Crackdown, March-In Support

Vice President Kamala Harris has made reducing drug prices a key talking point as she kicks off her campaign for president, and the presumptive Democratic nominee’s prior calls for NIH to employ its march-in authority and her crackdowns on noncompetitive industry behavior signal she would give NIH and the Federal Trade Commission key roles in policing the pharmaceutical industry if elected president in November. NIH’s draft framework for NIH to for the first time use its March-in tool to lower...